Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample

Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample

US Patent 11594403 · Granted Feb 28, 2023

Estimated economic value: $4,500,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Apparatus and method for identification of primary immune resistance in cancer p2024
Apparatus and method for identification of primary immune resistance in cancer p2024
Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitaliz2024
Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitaliz2024
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy2023
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy2023
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy2023
Classifier generation methods and predictive test for ovarian cancer patient pro2023
Classifier generation methods and predictive test for ovarian cancer patient pro2023
Classifier generation methods and predictive test for ovarian cancer patient pro2023